ZBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ZBH is not a good buy right now. The chart remains in a bearish structure (SMA_200 > SMA_20 > SMA_5) with weak momentum, the pattern-based forward bias also points lower over the next month, and near-term headline risk (legal investigations tied to guidance/credibility) plus an upcoming earnings catalyst (2026-02-10 pre-market) makes the risk/reward unattractive for an impatient buyer. Options flow is call-heavy, but it is not strong enough to override the bearish trend + negative news backdrop. Best call: avoid buying here (sell/stand aside).
Trend/Momentum: Bearish trend setup with moving averages stacked down (SMA_200 > SMA_20 > SMA_5), indicating the prevailing trend is still down. MACD histogram is negative (-0.152) but contracting, suggesting downside momentum is slowing—not reversing. RSI(6) 48 is neutral, consistent with a weak/indecisive bounce rather than a confirmed uptrend.
Key levels: Pivot 86.854 is essentially the current area (86.99). Immediate resistance at 88.645 (R1) then 89.752 (R2). Support at 85.062 (S1) then 83.955 (S2). Given the bearish MA structure, rallies into 88.6–89.8 look more like sell-rally zones unless price reclaims and holds above them.
Stat/pattern cue: Similar-candlestick study suggests ~80% odds of -0.16% next day, -0.95% next week, and -9.15% next month—aligning with the bearish trend bias.
Intellectia Proprietary Trading Signals Intellectia Proprietary Trading Signals
Analyst-side upside cases emerged: Evercore upgrade to Outperform (PT $
and TD Cowen upgrade to Buy (PT $109), arguing for improving growth/profit story and valuation re-rating potential.
Sector backdrop: Bernstein notes improving tone for U.S. healthcare stocks into 2026 as macro/policy uncertainty clears.
Q3 2025 revenue growth was strong (+9.71% YoY), and gross margin improved (+1.43% YoY).
Credibility/headline risk: Multiple law-firm/investigation headlines (Hagens Berman and follow-on investigation) centered on revenue guidance and management credibility.
Prior operational disruption: 15% stock drop tied to reduced revenue guidance and emerging-market distributor order cancellations (Nov
remains an overhang.
Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-10 (pre-market) can amplify downside if growth/margins or guidance disappoint.
Technical/breadth: Bearish moving-average stack and pattern-based outlook pointing to further downside over the next month.
Latest reported quarter: 2025/Q3. Revenue rose to $2.001B (+9.71% YoY), but profitability weakened: net income $230.9M (-7.31% YoY) and EPS 1.16 (-5.69% YoY). Gross margin improved to 63.24% (+1.43% YoY). Summary: top-line growth is positive, but earnings are not keeping pace—consistent with the market’s concerns about execution/consistency. Insiders/Hedge funds: Both are described as Neutral with no significant recent trend. Congress trading: No recent congress trading data available.
Recent trend: Ratings and price targets are mixed, with notable dispersion.
